Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1252 participants.

Also called NCT04763200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,252 participants (planned count) (from the registry)
Sponsor
  • Abiomed Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04763200
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada, Germany, Italy, Netherlands, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04763200. Randomized; no masking; primary purpose treatment. Start 2021-04-13 (actual); primary completion 2026-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
Acronym
PROTECT IV
Condition
Left Ventricular Dysfunction
Intervention (Device)
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®
Intervention (Device)
IABP Intra-aortic balloon pump
Lead sponsor
Abiomed Inc. (class: industry)

Record details

Record id
cardio:ct-nct04763200
Content hash
897f5e2ab72cf3f6679337bb5f2cf0129e03c37c2f4caa2bd02a102816c083db